2023-507321-42-00招募中1 期
A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 53
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Team
Scientific
Schrodinger Inc.
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CRelapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CTIS2023-504403-92-00Janssen - Cilag International200
招募中
1 期
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL2023-509258-71-00Janssen Cilag International30
招募中
1 期
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL2023-504403-92-00Janssen - Cilag International60
尚未招募
不适用
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myelomamultiple myelomaNL-OMON53500Janssen-Cilag12
进行中（未招募）
1 期
A study of JNJ-79635322 in participants with relapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisRelapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosisCancerISRCTN13185938Janssen Research & Development, LLC140